

Obstructive sleep apnea is common in patients with high-impact chronic pain - an exploratory study from an interdisciplinary pain center

Larsen, Dennis Boye; Bendix, Laila; Abeler, Karin; Petersen, Kristian Kjær; Sprehn, Michael; Bruun, Karin Due; Blichfeldt-Eckhardt, Morten Rune; Vaegter, Henrik Bjarke

Published in:
Scandinavian Journal of Pain

DOI:
10.1515/sjpain-2021-0112

Publication date:
2022

Document version:
Final published version

Citation for pulished version (APA):

Larsen, D. B., Bendix, L., Abeler, K., Petersen, K. K., Sprehn, M., Bruun, K. D., Blichfeldt-Eckhardt, M. R., & Vaegter, H. B. (2022). Obstructive sleep apnea is common in patients with high-impact chronic pain - an exploratory study from an interdisciplinary pain center. *Scandinavian Journal of Pain*, 22(1), 106-117. <https://doi.org/10.1515/sjpain-2021-0112>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Clinical Pain Research

Dennis Boye Larsen, Laila Bendix, Karin Abeler, Kristian Kjær Petersen, Michael Sprehn, Karin Due Bruun, Morten Rune Blichfeldt-Eckhardt and Henrik Bjarke Vaegter*

Obstructive sleep apnea is common in patients with high-impact chronic pain – an exploratory study from an interdisciplinary pain center

<https://doi.org/10.1515/sjpain-2021-0112>

Received June 28, 2021; accepted September 27, 2021;

published online October 12, 2021

Abstract

Objectives: Sleep disturbances are increasingly recognized as a major part of chronic pain pathology. Obstructive sleep apnea (OSA) is a common occurrence in patients with chronic pain attending specialized pain clinics, yet its prevalence remains unclear. Using screening tools such as the Berlin and STOP-BANG questionnaires may aid in early identification of OSA and improve clinical care. This study i) examined the frequency of OSA based on objective sleep monitoring in patients with high-impact chronic pain, ii) explored potential differences in self-reported pain and sleep characteristics between patients with and without

OSA, and iii) tested the agreement between OSA classification based on objective assessment and two OSA screening questionnaires.

Methods: A consecutive cohort of 90 patients (71 women and 19 men; mean age: 47.1 ± 11.0 years) referred for interdisciplinary pain treatment, underwent one night of sleep monitoring using portable respiratory polygraphy (RP), and suspected OSA was confirmed with polysomnography (PSG). Self-reported data on clinical pain (severity, pain drawings and health-related quality of life), sleep characteristics (sleep quality insomnia, sleepiness), and risk of OSA (Berlin and STOP-BANG questionnaires) were collected the day before RP assessment.

Results: Forty-six (51.1%) patients were classified with OSA according to RP and verified with PSG. Twenty-eight patients (31.1%) had moderate or severe OSA (apnea-hypopnea index [AHI] >15). Patients with OSA reported lower sleep quality compared with patients without OSA. Scores on pain severity, disability, quality of life, insomnia and sleepiness were comparable between patients with and without OSA. Sensitivity and specificity were 78.6 and 45.2% respectively for the Berlin questionnaire, and 71.4 and 58.1% respectively for the STOP-BANG questionnaire. The agreement for both questionnaires with objective assessment was poor-to-fair. Both questionnaires had acceptable negative predictive values but low positive predictive values reducing the clinical utility to identify patients with low OSA-risk in this sample.

Conclusions: The current study demonstrates a high prevalence of OSA in patients with high-impact chronic pain referred to specialized pain treatment, however the clinical pain profiles were similar in patients with and without OSA. The Berlin and STOP-BANG questionnaires have poor specificity and low-to-fair agreement with RP/PSG questioning their clinical utility in identifying OSA in this sample.

Keywords: Berlin; chronic pain; OSA; respiratory polygraphy; sleep; STOP-BANG.

*Corresponding author: **Henrik Bjarke Vaegter**, PhD, Department of Anesthesiology and Intensive Care Medicine, Pain Research Group, Pain Center, University Hospital Odense, Odense, Denmark; and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Heden 7-9, Indgang 200, DK – 5000, Odense C, Denmark, Phone: +45 65413869, Fax: +45 65415064, E-mail: hbv@rsyd.dk. <https://orcid.org/0000-0002-7707-9947>

Dennis Boye Larsen and Kristian Kjær Petersen, Department of Health Science and Technology, SMI, School of Medicine, Aalborg University, Aalborg, Denmark; and Department of Health Science and Technology, Center for Neuroplasticity and Pain (CNAP), SMI, School of Medicine, Aalborg University, Aalborg, Denmark

Laila Bendix, Department of Anesthesiology and Intensive Care Medicine, Pain Research Group, Pain Center, University Hospital Odense, Odense, Denmark

Karin Abeler, Department of Neurology and Neurophysiology, University Hospital of North Norway, Tromsø, Norway

Michael Sprehn, Department of Anesthesiology and Intensive Care Medicine, Respiration Center South, University Hospital Odense, Odense, Denmark

Karin Due Bruun and Morten Rune Blichfeldt-Eckhardt, Department of Anesthesiology and Intensive Care Medicine, Pain Research Group, Pain Center, University Hospital Odense, Odense, Denmark; and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Introduction

Chronic pain, recognized by the International Association for the Study of Pain (IASP) as pain that persists longer than 3 months [1], remains a major societal challenge given its contribution to years lived with disability [2]. Several lines of evidence have shown associations between a variety of chronic pain conditions and psychological factors such as pain catastrophizing [3], depression [4], and anxiety [5]. However, a recent systematic review highlighted the need for a better understanding of underlying factors for chronic pain [6]. Earlier evidence has demonstrated that partial [7] and total sleep deprivation [8] may affect central pain mechanisms, indicating that regular sleep is important to maintain a healthy response to pain. Indeed, a frequent complaint in chronic pain is disturbance of sleep, where an estimated 66–88% of patients with chronic pain report low-quality sleep [9–11]. While a recent review on polysomnographic findings in nonmalignant chronic pain, reported a non-consistent pattern of objective sleep disturbances [12], recent meta-analyses [13, 14] reported that chronic pain and fibromyalgia patients experience sleep disturbances involving sleep initiation and maintenance. Other studies have shown that sleep disturbances plays a pivotal part in chronic pain pathology [15, 16]. For instance, a recent machine learning study on 277 patients undergoing tertiary pain management, demonstrated that patients with severe pain were often characterized as having sleep problems along with more pain areas, greater affective pain interference, fear of pain, and lower self-rated health [17]. In this respect, sleep disordered breathing (SDB) is a prevalent sleep problem that has been reported as high as 32–82% in women with fibromyalgia [18, 19]. Obstructive sleep apnea (OSA) is the most common type of SDB. OSA is clinically characterized by excessive daytime sleepiness, insomnia, fatigue or decreased quality of life [20, 21] and is diagnosed by sleep recordings – respiratory polygraphy (RP) or polysomnography (PSG) – quantifying apneas and hypopneas per hour in the apnea-hypopnea index (AHI). In an elderly population it was shown that subjects diagnosed with OSA also exhibited increased pain sensitivity [22]. It therefore seems evident that sleep and pain are intimately linked, and even if concurrent treatment of pain and sleep impairment is warranted, this is rarely done in a systematic manner [23]. Traditionally, sleep disturbances in patients with chronic pain have been based on self-reported questionnaires on e.g. poor, non-restorative sleep with multiple nightly awakenings

[10, 24], whereas the current gold-standard for assessing sleep disturbances is polysomnography as is utilized in e.g. OSA [25]. However, since PSG requires technical prowess and is expensive to utilize [26, 27], the clinical implementation for assessment of SDB in patients with chronic pain presents a challenge, even if screening for e.g. OSA may be relevant in this population [9]. Further, it remains unclear if OSA screening questionnaires such as the Berlin [28] and the STOP-BANG [29] questionnaires may inform on OSA presence in agreement with objective findings in chronic pain patients [12].

Therefore, the current study aimed to explore the frequency of OSA based on objective sleep monitoring in patients with high-impact chronic pain, defined as persistent pain with substantial restriction of life activities lasting 6 months or more [30], referred for interdisciplinary pain treatment. Secondary aims were to identify possible differences in clinical pain characteristics between patients with and without OSA, and to determine the agreement in classification of OSA between the objective assessment and two OSA screening questionnaires (the Berlin questionnaire and the STOP-BANG questionnaire). Based on earlier evidence we hypothesized (1) high prevalence of OSA in the current sample; (2) patients with OSA would present with worse clinical characteristics when compared to no-OSA patients; and (3) that subjective questionnaires (Berlin and STOP-BANG) would show high agreement with objective OSA classification [28, 31].

Methods and materials

Patient population

Patients between 18 and 65 years of age referred for interdisciplinary pain treatment at the University Hospital Pain Center in Odense, Denmark between January and December 2017, were included as part of the everyday clinic. Exclusion criteria were inability to understand Danish and currently undergoing treatment for sleep apnea. All patients referred to the Pain Center have chronic (>6 months) non-cancer pain conditions and have previously tried a number of treatments in primary and secondary care settings with an unsatisfactory clinical response. Patients in this setting have moderate to severe pain intensity, high disability, and psychological distress, and most report pain in more than one body area [32–34]. This exploratory and observational cohort study was registered and approved by the local ethics committee (S-20160129) and The Danish Data Protection Agency and was conducted in accordance with the Declaration of Helsinki.

Procedure

During the initial visit to the Pain Center, patients were informed about the study. Patients who consented to participate were scheduled for a clinical examination on a separate day. At this visit patients completed the questionnaires and underwent a clinical examination. Hereafter, patients were instructed how to use the sleep monitoring device, and underwent one night of sleep monitoring the following night.

Monitoring of obstructive sleep apnea

To evaluate the presence of OSA, all patients underwent one night of sleep monitoring with a portable RP sleep device (NOX T3™, NOX Medicals, Iceland). RP is an accepted modality for diagnosing OSA by the third edition of the International Classification of Sleep Disorders (ICSD-3) [35]. The NOX T3™ was originally validated for detecting OSA by assessing airflow (cannula pressure transducer), thoracic and abdominal respiratory effort (respiratory inductance plethysmography), wireless pulse oximetry, body position, snoring, actigraphy, and audio, and has good measure agreement with polysomnography (PSG) [36]. Abnormal (AHI >5) or inconclusive RP results were confirmed by PSG at the Odense University Hospital Respiration Center within approximately 2 weeks after the RP.

Polysomnography

NOX A1 equipment and software from NOX medical version 5.1.3.20388, were used for PSG, and the recording and scoring were performed by trained clinicians in accordance with The American Academy of Sleep Medicine (AASM) Manual for the Scoring of Sleep and Associated Events, version 2.5 [37]. Six electroencephalogram leads (F3/F4, C3/C4, O1/O2), right and left electro-oculogram, and submental electromyogram were used for sleep scoring. Pressure flow nasal cannula, inductive thoracic and abdominal belts (effort), and oximetry were used for respiratory assessment, and the AASM hypopnea scoring rule 1A was applied (≥ 10 s duration of $\geq 30\%$ of air flow reduction associated with a $\geq 3\%$ decrease in oxygen saturation and/or an electroencephalographic arousal). Apneas were scored when there were a 90% drop in the flow signal lasting 10 or more seconds. The apnea-hypopnea index (AHI) is used to grade the severity of OSA into mild OSA, defined as AHI of 5–15, and moderate-severe OSA defined as AHI ≥ 15 [38].

Clinical examination

Prior to sleep monitoring, patients were assessed by a pain specialist from the Pain Center and based on pain distribution and pain history patients were classified into one of the following pain conditions: widespread pain, radiating back/neck pain, neuropathic pain condition or regional/localized pain.

Height, weight, blood pressure, neck circumference, and Mallampati score were measured by a trained nurse. The Mallampati score is categorized in four classes, based on a visual assessment of the distance from the tongue base to the roof of the mouth. A higher

class indicating less space, has been associated with higher incidence of OSA [39].

Questionnaire data

A web-based questionnaire system (PainData) was used to collect data on demographics (sex, age), clinical pain characteristics and sleep (quality, insomnia, sleepiness, risk of OSA) was completed at the hospital prior to the clinical examination [40].

Assessment of pain intensity and health-related quality of life: Peak and average pain intensity during the last 24 h were assessed on two 11-point numeric rating scales ranging from 0 (no pain) to 10 (worst imaginable pain) [41], which has been shown to be reliable and valid [42]. Furthermore, patients completed pain drawings indicating all locations – divided into 71 body areas – with pain during the previous week [40].

Health-related quality of life (QOL) was assessed using the 0–100 Visual Analog Scale (VAS) included in the EuroQol 5-D questionnaire with 100 indicating the best QOL [43].

Sleep-related questionnaires and assessment of risk factors for OSA:

Sleep quality was assessed using the four items from the Karolinska Sleep Questionnaire (KSQ) sleep quality subscale, assessing frequency of sleep disturbance, early awakenings, difficulties falling asleep and night time awakenings with difficulty returning to sleep [44, 45]. In the Danish version of the KSQ, participants respond using one of five categories (1 = every night or almost every night, 2 = several times a week, 3 = several times a month, 4 = several times a year, 5 = never). The questions and response options used in this study have previously been used to explore sleep difficulties in a large Danish study [46].

Insomnia was assessed with the Insomnia Severity Index (ISI) which encompasses seven items measuring severity of sleep-onset; sleep maintenance and early morning awakening difficulties; satisfaction with sleep patterns; daily function interference; impairments due to sleep problems; and distress or concerns due to sleep problems [47]. Each item is rated from 0 to 4 (0 = no problem, 4 = severe problem), yielding a total score of 28, with higher scores reflecting worse insomnia, and is validated for use in research [48] and primary care [49].

Daytime sleepiness was assessed with the Epworth Sleepiness Scale (ESS). The subjects rate their chance of dozing off or falling asleep in eight different daytime situations, on a 4-point Likert scale (0 = would never doze, 3 = high chance of dozing). ESS scores greater than 11 is indicative of excessive daytime sleepiness [50].

Risk factors for OSA was evaluated by the Berlin questionnaire and The STOP-BANG questionnaire, which screens for the probability of OSA. The Berlin Questionnaire spans three categories, snoring/gasping; daytime somnolence; and hypertension/BMI. Patients with a positive score in two or more categories are considered at high-risk for OSA [28]. The STOP-BANG questionnaire [31] is a four-item forced yes/no questionnaire which assesses snoring; tiredness, fatigue, or daily sleepiness; external observation of cessation of breathing; and blood pressure, and is validated in e.g. patients undergoing elective surgery [31], and patients referred to sleep clinics [29]. Three or more positive responses on the questionnaire indicate

higher risk of OSA with BMI greater than 35 kg/m², age older than 50, male gender, and neck circumference greater than 40 cm greatly increasing the predictive value for OSA [31].

Statistical analysis

All statistical analyses were performed in SPSS version 24 (IBM Corporation, Armonk, NY). $p < 0.05$ was considered significant, and due to the exploratory nature of the study, p -values were not adjusted for multiple comparisons.

Descriptive data for objective sleep monitoring and questionnaire data on demographics, pain characteristics and sleep are reported as count and proportions (%) with 95% confidence intervals or means and SDs. For exploration of potential differences between patients with and without OSA, t -tests or χ^2 tests were used. Possible differences between patients with mild OSA and moderate to severe OSA vs. no OSA were explored using one-way analysis of variance (ANOVA). In addition, because of the different gender ratios between groups and the significant differences between men and women in clinical pain parameters, all parameters were gender adjusted by z -transformation by subtraction of the mean values divided by the SD for men and women, respectively.

To explore performance characteristics of the Berlin questionnaire and the STOP-BANG questionnaire, contingency tables were made using objective RP (verified by PSG) as reference standard. Data were derived from the tables to calculate sensitivity, specificity, positive and negative likelihood ratios, and positive and negative post-test probabilities. The sensitivity measure is the proportion of patients correctly identified with OSA by the questionnaire (compared to reference). The specificity measure is the proportion of patients correctly identified as not having OSA by the questionnaire. The positive and negative post-test probability measures are the probabilities of the presence of OSA after scoring above or below cut-off on the respective questionnaires. The positive predictive value reflects the probability that a patient is classified with OSA by the questionnaire and the objective assessment. Conversely, the negative predictive value is the probability that a patient is considered no-OSA by the questionnaire and the objective assessment.

Cohen's kappa coefficient was used to explore agreement between objective and subjective (Berlin Questionnaire and the STOP-BANG) classification of OSA. Kappa values of 0.81–1.0 was interpreted as almost perfect agreement, 0.61–0.80 as substantial agreement, 0.41–0.60 as moderate agreement, 0.21–0.40 as fair agreement, and 0.0–0.20 as poor agreement [51].

Results

In total, 91 patients were enrolled in the study, but due to complications with sleep while using the provided equipment, one patient withdrew. Therefore, 90 patients (71 women and 19 men; mean age: 47.1 ± 11.0 years) were enrolled in this exploratory study. Based on the clinical examination, patients were classified into the following pain conditions: widespread pain (58%), radiating back pain (13%), neuropathic pain (4%), and regional pain

(25%). The average pain duration was 12.3 years (range: 10 months to 44 years).

Frequency of sleep disordered breathing

Forty-six of the 90 patients were diagnosed with OSA on RP and verified by PSG (prevalence of 51.1% [95% CI 40.3–61.8%]). Twenty-eight patients had moderate to severe OSA (prevalence of 31.1% [95% CI 21.8–41.7%]), and 18 patients had mild OSA (prevalence of 20% [95% CI 11.7–28.3%]).

Self-reported socio-demographics, pain and sleep characteristics in patients with and without OSA

As illustrated in Table 1, patients in the OSA group were more often men, had higher age and BMI and neck circumference compared with patients in the no-OSA group. These differences were mainly explained by differences between patients with moderate to severe OSA compared with patients with no OSA. In addition, the score on the KSQ sleep quality subscale was lower in the OSA group compared with the no-OSA group. This between-group difference was mainly due to differences in the proportions of patients with frequent repeated awakenings and early awakenings. No significant differences were observed for clinical pain characteristics, insomnia, or sleepiness. As illustrated in Table 2, similar findings were observed for the gender-adjusted values.

Performance characteristics for the two OSA screening questionnaires

In total, 56 patients (62.2%) were classified with high risk of OSA based on the Berlin Questionnaire. The contingency table is presented in Table 3 and performance characteristics are shown in Table 4. The Berlin questionnaire showed a sensitivity of 78.6% (correctly identified by the questionnaire as OSA) and a specificity of 45.2% (correctly identified by the questionnaire as not having OSA). The negative predictive value was 82% (i.e. the probability that a patient with a negative questionnaire is also classified as no-OSA by the objective assessment). The positive predictive value was 39% (i.e. the probability that a patient with a positive questionnaire is also classified with OSA based by the objective assessment). Examination of the agreement in classification of OSA based on the questionnaire vs.

Table 1: Demographics, pain and sleep characteristics for chronic pain patients with and without obstructive sleep apnea (OSA). OSA is divided into mild apnea-hypopnea index (AHI: 5–15) and moderate-severe (AHI>15) OSA based on polysomnography (PSG) assessment.

Variables	No OSA (n=44)	OSA (n=46)			Group-wise comparisons	
		All OSA (n=46)	Mild OSA (n=18)	Moderate-severe OSA (n=28)	No OSA vs. all OSA p-value and post hoc	No OSA vs. mild vs. moderate to severe OSA subgroups p-value and post hoc
Sex, F, %	39 (54.9)	32 (45.1)	14 (19.7)	18 (25.4)	0.027, No OSA > OSA	0.047, No OSA > Mod-Sev OSA
Age, years	42.7 ± 10.4	51.2 ± 10.1	49.7 ± 11.2	52.3 ± 9.4	<0.001, No OSA < OSA	0.001, No OSA < Mod-Sev OSA
BMI, kg/m ²	29.0 ± 6.2	32.8 ± 6.5	31.2 ± 5.3	33.8 ± 7.1	0.006, No OSA < OSA	0.01, No OSA < Mod-Sev OSA
Neck width, cm	36.9 ± 3.4	40.3 ± 3.8	38.8 ± 3.1	41.3 ± 4.0	<0.001, No OSA < OSA	<0.001, No OSA < Mod-Sev OSA
Mellampati score (score 1–4)	2.0 ± 1.0	1.7 ± 0.8	1.7 ± 0.8	1.8 ± 0.8	0.26	0.49
Systolic blood pressure	127.7 ± 17.3	135.8 ± 20.0	131.9 ± 23.3	139.4 ± 16.3	0.09	0.14
Diastolic blood pressure	86.1 ± 10.4	89.1 ± 11.7	87.4 ± 12.9	90.8 ± 10.7	0.29	0.40
Peak pain intensity (NRS: 0–10, higher scores are worse)	7.3 ± 1.8	7.7 ± 1.8	7.4 ± 1.9	7.9 ± 1.8	0.32	0.41
Average pain intensity (NRS: 0–10)	5.9 ± 2.0	6.7 ± 1.9	6.2 ± 2.0	7.0 ± 1.8	0.06	0.08
Pain areas (n/71)	27.3 ± 19.1	24.0 ± 15.0	26.1 ± 15.6	22.7 ± 14.8	0.39	0.58
Current opioid use, %	28.6	43.6	33.3	50.0	0.16	0.21
EQ5D-VAS (0–100, lower scores are worse)	44.2 ± 20.7	43.2 ± 22.5	38.8 ± 21.6	46.0 ± 23.1	0.85	0.59
Sleep quality (KSQ: 1–5, lower scores are worse)	2.2 ± 1.0	1.7 ± 0.9	1.7 ± 1.3	1.7 ± 0.6	0.02 No OSA > OSA	0.06
Difficulties falling asleep (% often or always)	64.3	73.7	64.3	79.2	0.37	0.42
Disturbed/poor sleep (% often or always)	81.0	89.5	85.7	91.7	0.29	0.50
Repeated awakenings (% often or always)	61.0	89.5	85.7	91.7	0.004, No OSA < OSA	0.013, No OSA > Mod-Sev OSA
Early awakenings (% often or always)	57.1	86.6	85.7	87.5	0.003, No OSA < OSA	0.014, No OSA > Mod-Sev OSA
Insomnia (ISI: 0–28, higher scores are worse)	15.2 ± 6.3	15.9 ± 5.7	16.4 ± 4.7	15.6 ± 6.3	0.55	0.75
Sleepiness (ESS: 0–24, higher scores are worse)	7.7 ± 4.7	7.6 ± 3.8	7.4 ± 3.9	7.8 ± 3.8	0.96	0.97

objective assessment showed a significant but poor agreement ($\kappa=0.18$ [95% CI: 0.03–0.35], $p=0.03$).

In total, 46 patients (51.1%) were classified with high risk of OSA based on the STOP-BANG questionnaire. The contingency table is presented in Table 3 and performance characteristics are shown in Table 4. The STOP-BANG questionnaire showed a sensitivity of 71.4% (correctly identified by the questionnaire as OSA) and a specificity of 58.1%. The negative predictive value was 82%. The positive predictive value was 44%. Examination of the agreement

in classification of OSA based on the questionnaire vs. objective assessment showed a significant and fair agreement ($\kappa=0.25$ [95% CI: 0.07–0.18], $p=0.01$).

Discussion

This study demonstrated a high frequency of 51.1% of patients with OSA, with 31.1% presenting the moderate-to-severe manifestation. Furthermore, gender-adjusted

Table 2: Mean (\pm SD) gender-adjusted Z-scores of demographics, pain and sleep characteristics for chronic pain patients with and without obstructive sleep apnea (OSA). OSA is further divided into mild apnea-hypopnea index (AHI: 5–15) and moderate-severe (AHI>15) OSA based on polysomnography (PSG) assessment. Positive Z-scores indicate increased parameters compared with the group mean.

Variables	No OSA (n=44)	OSA (n=46)			Group-wise comparisons	
		All OSA (n=46)	Mild OSA (n=18)	Moderate-severe OSA (n=28)	No OSA vs. all OSA p-value and post hoc	No OSA vs. mild vs. moderate to severe OSA subgroups p-value and post hoc
Age	-0.36 \pm 0.93	0.34 \pm 0.93	0.24 \pm 0.96	0.41 \pm 0.93	0.001, No OSA < OSA	0.002, No OSA < Mod-Sev OSA
BMI, kg/m ²	-0.32 \pm 0.91	0.32 \pm 0.98	0.01 \pm 0.75	0.52 \pm 1.10	0.002, No OSA < OSA	0.002, No OSA < Mod-Sev OSA
Neck width, cm	-0.37 \pm 0.92	0.36 \pm 0.94	0.05 \pm 0.77	0.57 \pm 0.99	<0.001, No OSA < OSA	<0.001, No OSA < Mod-Sev OSA
Mellampati score (score 1–4)	0.12 \pm 1.09	-0.12 \pm 0.89	-0.18 \pm 0.93	-0.08 \pm 0.87	0.26	0.49
Systolic blood pressure	-0.16 \pm 0.86	0.15 \pm 1.10	-0.05 \pm 1.18	0.34 \pm 1.02	0.23	0.27
Diastolic blood pressure	-0.09 \pm 0.90	0.08 \pm 1.08	-0.08 \pm 1.19	0.23 \pm 0.99	0.51	0.56
Peak pain intensity (NRS: 0–10)	-0.08 \pm 1.0	0.08 \pm 0.99	-0.06 \pm 1.05	0.17 \pm 0.97	0.46	0.57
Average pain intensity (NRS: 0–10)	-0.19 \pm 1.00	0.18 \pm 0.96	-0.03 \pm 1.02	0.32 \pm 0.91	0.08	0.11
Pain areas (n/71)	0.07 \pm 1.12	-0.07 \pm 0.85	0.05 \pm 0.95	-0.15 \pm 0.80	0.54	0.70
EQ5D-VAS (0–100)	-0.01 \pm 1.00	0.02 \pm 1.00	-0.16 \pm 0.96	0.13 \pm 1.02	0.89	0.67
Sleep quality (KSQ: 1–5)	0.22 \pm 1.05	-0.24 \pm 0.88	-0.24 \pm 1.24	-0.24 \pm 0.61	0.04 No OSA > OSA	0.11
Insomnia (ISI: 0–28)	-0.08 \pm 1.05	0.08 \pm 0.94	0.15 \pm 0.78	0.03 \pm 1.04	0.46	0.70
Sleepiness (ESS: 0–24)	-0.03 \pm 1.13	0.03 \pm 0.86	-0.04 \pm 0.88	0.07 \pm 0.87	0.81	0.91

Table 3: Contingency tables comparing the Berlin questionnaire and STOP-BANG questionnaire classifications of moderate to severe obstructive sleep apnea against objective assessment with respiratory polygraphy (RP) and positive cases verified by polysomnography (PSG) as reference standard.

Berlin questionnaire	Objective assessment		Total
	OSA (Yes)	OSA (No)	
Positive OSA	22	34	56
Negative OSA	6	28	34
Total	28	62	90

STOP-BANG questionnaire	Objective assessment		Total
	OSA (Yes)	OSA (No)	
Positive OSA	20	26	46
Negative OSA	8	36	44
Total	28	62	90

estimates of pain characteristics, reports of insomnia, and sleepiness did not differ between OSA and no-OSA groups.

Performance characteristics of the Berlin questionnaire showed a sensitivity of 76.8% and specificity of 45.2%, with a significant but poor agreement with objective RP assessments. The STOP-BANG questionnaire had a sensitivity of 71.4% and specificity of 58.1%, with a significant fair agreement with RP assessments. Both questionnaires had acceptable negative predictive values but low positive predictive values indicating a potential clinical utility of identifying patients with low risk of OSA in this sample.

Prevalence of OSA in patients with high-impact chronic pain referred for interdisciplinary treatment

In the current study, 51.1% of patients with high-impact chronic pain were diagnosed with clinical OSA. This finding is in agreement with a recent study on predictive factors for OSA in patients with chronic pain, where 58.8% of patients

Table 4: Performance characteristics of the Berlin questionnaire and STOP-BANG questionnaire for classification of moderate to severe obstructive sleep apnea, using objective assessment with respiratory polygraphy (RP) and positive cases verified by polysomnography (PSG) as reference standard.

	Sensitivity	Specificity	Positive like- lihood ratio	Negative like- lihood ratio	Positive post- test probability	Negative post- test probability	Positive pre- dictive value	Negative pre- dictive value
Berlin	0.79 (0.64– 0.94)	0.45 (0.33–0.58)	1.43 (1.06– 1.93)	0.47 (0.22– 1.02)	0.39 (0.27–0.52)	0.18 (0.05– 0.31)	0.39 (0.27– 0.52)	0.82 (0.70–0.95)
STOP-BANG	0.71 (0.55– 0.88)	0.58 (0.46– 0.70)	1.70 (0.17– 2.48)	0.49 (0.26– 0.92)	0.44 (0.29–0.58)	0.18 (0.07– 0.30)	0.44 (0.29– 0.58)	0.82 (0.70– 0.93)

presented with OSA [52], and a recent meta-analysis on 37 studies which estimated a pooled prevalence of 44% (32% for OSA) for clinically diagnosed sleep disorders in a broad population of patients with chronic pain [13]. Furthermore, the prevalence of moderate-severe OSA is similar to a recent study investigating sleep characteristics in chronic musculoskeletal pain patients (31.1 and 28.6%, respectively) [53]. The prevalence of OSA in the current cohort is much greater than what has been estimated in the general population. For instance, the well-known Wisconsin Sleep Cohort Study estimated the prevalence of SDB to be 6.5% in women, and 17% in men, whereas a more recent population-based study investigated 2,121 people and reported a prevalence of 23.4% in women and 49.7% in men [54, 55]. As such, even if the estimated prevalence of SDB in the general population may increase due to advancements in technology and guidelines [37] for the diagnosis of e.g. OSA [56], it is important to recognize the high prevalence in chronic pain populations. In a large-scale retrospective study, an OSA prevalence of 13.8% out of 4,036 chronic spinal pain patients was reported [57]. Furthermore, sleep disturbances are commonly reported in patients with fibromyalgia [18] and osteoarthritis [58, 59]. The current study supports and extends these findings by showing a similar high prevalence of diagnosed OSA in patients with high-impact chronic pain referred for interdisciplinary treatment. As it is known that OSA incidence increase with age (in particular between ages 40–60) [60], it should be considered if the higher prevalence reported here, is due to age differences between the included participants and earlier study cohorts. When compared to the Wisconsin Sleep Cohort study, the included cohort is younger (48.4 ± 7.7 years vs. 47.1 ± 11 , respectively) [55], and similarly younger when compared to a recent large-scale OSA study in the general population [61]. Age alone, can therefore not explain the higher prevalence in OSA in our sample of high-impact chronic pain patients. It is also worth noting that half of the current sample was on prescription opioids for pain management, however no

difference in opioid use between mild and moderate-to-severe OSA was found. However, it is important to note that the current study was not powered to investigate differences in opioid use in mild vs. moderate-to-severe OSA. Similar percentages of opioid use were reported in a recent large-scale study in more than 12,000 patients with high-impact chronic pain in Denmark [40] which found that 39.1% of women and 51% men were using opioids at the time of attendance. Opioid-induced SDB has been extensively studied [62–64], and a recent systematic review and meta-analysis reported a SDB prevalence of 63 and 91% in non-cancer chronic pain patients on prescription opioids, attending pain or sleep clinics, respectively [65].

Clinical characteristics in patients with and without OSA

Findings from the current study did not suggest a difference in pain intensity, insomnia complaints or sleepiness when comparing patients with and without OSA, although scores on average pain intensity approached significance suggesting higher pain intensity in patients with moderate to severe OSA. A recent systematic review found substantial differences in pain outcomes (increased pain intensity or decreased pain tolerance) when comparing patients with and without OSA [66].

Co-occurrence of OSA and insomnia is well-established [67], and an explanation for the discrepant findings may be, that since insomnia complaints were not different between the groups, sleep disturbances were not of sufficient magnitude to affect general pain perception as seen in e.g. knee osteoarthritis patients with and without insomnia [68]. It could be speculated that co-morbid insomnia may be one mediating factor for increased pain perception in high-impact chronic pain patients, independent of clinical OSA or not, but is outside the scope of the current report.

Conversely, KSQ sleep quality was significantly worse for the OSA group when compared to the no-OSA group. While patients with high-impact chronic pain have increased mortality rates when compared to the general population [69], it is still unclear if and how the high prevalence of OSA may affect this. However, OSA is associated with increased risk of cardiovascular diseases, e.g. through intermittent hypoxemia, vascular endothelial dysfunction, and oxidative stress [70], and is known to increase all-cause mortality [71]. This emphasizes the importance of early identification of OSA in patients with chronic pain, since a recent state-of-the-art article outlined that the use of continuous positive airway pressure effectively improved quality of life, mood, and work productivity, and lowers risk of cardiovascular events [72]. As such, future studies are encouraged to investigate the prevalence of OSA in patients with chronic pain and its association with mortality and e.g. comorbid cardiovascular diseases.

In the current study, there was a lower proportion of patients in the no-OSA group reporting frequent repeated and early awakenings on the KSQ as compared to the OSA groups, with a possible dose-response pattern with more repeated and early awakenings, the worse the sleep problems become. This, however, remains a speculation for now, given the sample sizes and potential power issues. Daytime sleepiness, as reflected by the ESS, and insomnia, as measured by the ISI, did not differ between the no-OSA and OSA groups, which is surprising since these are two of the main symptom clusters related to OSA. Possible explanations are that the OSA measure (current AHI-scoring) is too sensitive thereby identifying less symptomatic patients or that there are characteristics related to having chronic pain that may mask OSA-symptoms. In contrast, an earlier large-scale study suggested an association between daytime sleepiness and SDB in men, but not in women [73], yet contrasting findings are available in e.g. atrial fibrillation patients [74] and general population [61]. As such, the utility of including the Epworth Sleepiness Scale in assessing potential OSA, remains questionable, which is further supported by the current study. For insomnia, Cho et al. [75] showed that in 476 patients with OSA, 29.2% of the patients also presented with insomnia, which is further supported by a recent systematic review and meta-analysis which estimated a 27–29% prevalence of insomnia in patients with OSA [76]. The current results suggest that while insomnia is reported in patients with chronic pain, this may not be related to the presence of co-morbid OSA. Future studies could focus on investigating the relationship between the

clinical presentation of e.g. mild vs. moderate to severe OSA and awakenings, and possibly how this may relate to pain as earlier evidence suggest that co-morbid OSA or insomnia may impact pain intensity reports in patients with chronic pain [77].

Classification of patients with high risk of OSA based on the Berlin and STOP-BANG questionnaire and performance characteristics

The Berlin questionnaire identified 62.2% of the cohort to be at high-risk for moderate-to-severe OSA. Similar findings were reported in a study on 316 patients recruited from respiratory clinics, where 69.7 and 77.5% were identified at high risk for OSA, depending on allocation into a home-based sleep test or hospital-based PSG group [78]. The sensitivity and specificity were found to be 78 and 23% when predicting an apnea-hypopnea index ≥ 15 as diagnosed by PSG [78]. The current study agrees with respect to the sensitivity, but with a higher specificity which may be due to the difference in patient populations included (patients with high-impact chronic pain vs. patients referred for suspected OSA). Moreover, a systematic review and meta-analysis on the performance characteristics of the Berlin questionnaire estimated a sensitivity and specificity of 69 and 83%, respectively in general populations and 69 and 56%, respectively in surgical populations, when using PSG as reference [79]. As such, the current findings support that the Berlin may have modest-to-high sensitivity for detecting OSA. However, as the Berlin questionnaire had an acceptable negative predictive value but a low positive predictive value it seems most useful for identifying patients with low OSA-risk in the current sample.

The STOP-BANG questionnaire identified 51.1% of the included patients to be at high-risk for OSA. In agreement, an earlier study found, that in 305 chronic pain patients, 58.2% of the patients screened positive for OSA by the STOP-BANG questionnaire [80]. Unfortunately, the previous study did not report on polysomnographic diagnosed OSA to confirm the validity of these findings. Another recent study conducted in 204 patients with chronic pain, found that for each one-unit increase in the STOP-BANG score, odds for moderate-to-severe OSA was increased by 70% [52]. The STOP-BANG questionnaire sensitivity and specificity for OSA in the current study

showed lower sensitivity and specificity when compared with earlier evidence (sensitivity and specificity for OSA: 92.9 and 43%) [31]. The discrepancy may be due to differences in the included populations, as the current study employed the STOP-BANG questionnaire in patients with high-impact chronic pain. In addition, the current results indicate that patients with OSA were older, had higher BMI, and larger neck circumference as compared with patients without OSA. Further, when compared to a recent large-scale publication in high-impact chronic pain [40], the included cohort had slightly higher BMI, which may have affected the performance of the STOP-BANG questionnaire. This is in line with the original STOP-BANG questionnaire validation study which also reported that BMI >35 kg/m², age >50 years, and neck circumference >40 cm greatly increased the positive predictive value for OSA [31]. Like the Berlin questionnaire, the STOP-BANG questionnaire had an acceptable negative predictive value but a low positive predictive value, and implementation of the STOP-BANG questionnaire may aid in identifying persons with low OSA risk in high-impact chronic pain patients.

Clinical implications

The STOP-BANG and Berlin questionnaire can be used to identify patients with low risk of OSA. Among those with a higher risk, and based on the current findings, it can be recommended that clinicians systematically ask high-impact chronic pain patients about their sleep patterns. This should also encompass plausible comorbidities such as insomnia, cardiovascular diseases, diabetes, as well as willingness to comply with the treatment (continuous positive airway pressure) for OSA, which has notoriously suboptimal compliance rates (reported 68–84%) [81].

Limitations

The current exploratory study has several limitations. Only 90 patients were included. This, however, is unlikely to have affected the reported sleep disturbances, as a recent large-scale study (n=12,257) in high-impact chronic pain [40] demonstrated similar percentage reports of difficulties falling asleep (64.3 vs. 67.6%, current findings vs. large-scale study, respectively), disturbed/poor sleep (81 vs. 80.5%), repeated awakenings (61 vs. 70.2%), and early awakenings (57.1 vs. 62%). One limitation is that data on the inclusion and retention rate are not available, and we can therefore not exclude that a predominance of patients

with greater sleep disturbances are represented in the current study. However, we find that unlikely as the percentages reporting sleep problems (as reported above) are similar to findings in other larger-scale studies. Furthermore, as no *a priori* sample size calculation was performed, the current study may be underpowered, particularly for the three group comparisons (no OSA vs. mild vs. moderate-to-severe OSA). It is suggested that findings between the three subgroups are interpreted with care. Another limitation is that PSG was solely performed when RP showed an AHI >5. RP is normally known to underestimate OSA since it does not take into account the actual sleep duration (total sleep time) and applies less sensitive scoring of hypopneas (based only on desaturations, not cortical arousals) [82]. We can therefore not rule out with certainty that OSA was present also in patients that did not undergo PSG. However, RP is an accepted modality for diagnosing OSA by ICSD-3 [35].

Conclusions

The current exploratory study demonstrates a high prevalence of OSA in patients with high-impact chronic pain referred for interdisciplinary pain treatment; however, the clinical pain profile was not worse in patients with OSA. While the percentage identified with high risk of OSA in this sample by the Berlin and STOP-BANG questionnaires was similar to earlier reports, the current findings report poor performance for both questionnaires, when evaluating the agreement with gold-standard diagnosis of OSA, questioning their clinical utility in identifying OSA in patients with high-impact chronic pain. Future studies are encouraged to investigate the benefit of including early screening questionnaires for OSA and whether interventional strategies to combat e.g. moderate-to-severe OSA may improve clinical outcomes in this sample.

Acknowledgments: The authors acknowledge the important work conducted by study nurse Eva McGehee, staff at Pain Center South, and all the patients who voluntarily participated in the study. ResMed Maribo is acknowledged for providing the NOX T3™ for the entire project period. They had no impact on design of the study, analysis of the data or content in the manuscript.

Research funding: No funding was received for this study. KKP is supported by the Aalborg University Talent Management Program (j.no. 771126). Center for Neuroplasticity and Pain (CNAP) is supported by the Danish National Research Foundation (DNRF121).

Competing interests: There are no actual or potential conflicts of interest for any of the authors.

Informed consent: Written informed consent was obtained from all patients included in this study.

Ethical approval: This study was approved by the local ethics committee (S-20160129) and The Danish Data Protection Agency.

References

1. Treede RD, Rief W, Barke A, Aziz Q, Bennett MI, Benoliel R, et al. A classification of chronic pain for ICD-11. *Pain* 2015;156:1003–7.
2. Vos T, Allen C, Arora M, Barber RM, Brown A, Carter A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016;388:1545–602.
3. Severeijns R, Vlaeyen JWS, Van Den Hout MA, Weber WEJ. Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment. *Clin J Pain* 2001;17:165–72.
4. Goesling J, Clauw DJ, Hassett AL. Pain and depression: an integrative review of neurobiological and psychological factors. *Curr Psychiatry Rep* 2013;15:421.
5. Wood TJ, Thornley P, Petruccioli D, Kabali C, Winemaker M, de Beer J. Preoperative predictors of pain catastrophizing, anxiety, and depression in patients undergoing total joint arthroplasty. *J Arthroplasty* 2016;31:2750–6.
6. Petersen KK, Vaegter HB, Stubhaug A, Wolff A, Scammell BE, Arendt-Nielsen L, et al. The predictive value of quantitative sensory testing. *Pain* 2021;162:31–44.
7. Smith MT, Edwards RR, McCann UD, Haythornthwaite JA. The effects of sleep deprivation on pain inhibition and spontaneous pain in women. *Sleep* 2007;30:494–505.
8. Staffe AT, Bech MW, Clemmensen SLK, Nielsen HT, Larsen DB, Petersen KK. Total sleep deprivation increases pain sensitivity, impairs conditioned pain modulation and facilitates temporal summation of pain in healthy participants. *PLoS One* 2019;14:e0225849.
9. Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. *J Pain* 2013;14:1539–52.
10. McBeth J, Wilkie R, Bedson J, Chew-Graham C, Lacey RJ. Sleep disturbance and chronic widespread pain. *Curr Rheumatol Rep* 2015;17:1.
11. Morin CM, Gibson D, Wade J. Self-reported sleep and mood disturbance in chronic pain patients. *Clin J Pain* 1998;14:311–4.
12. Bjurstrom MF, Irwin MR. Polysomnographic characteristics in nonmalignant chronic pain populations: a review of controlled studies. *Sleep Med Rev* 2016;26:74–86.
13. Mathias JL, Cant ML, Burke ALJ. Sleep disturbances and sleep disorders in adults living with chronic pain: a meta-analysis. *Sleep Med* 2018;52:198–210.
14. Wu YL, Chang LY, Lee HC, Fang SC, Tsai PS. Sleep disturbances in fibromyalgia: a meta-analysis of case-control studies. *J Psychosom Res* 2017;96:89–97.
15. Lautenbacher S. Sleep and pain are definitely coupled—but how tight is this coupling? *Pain* 2018;159:3–4.
16. Afolalu EF, Ramlee F, Tang NKY. Effects of sleep changes on pain-related health outcomes in the general population: a systematic review of longitudinal studies with exploratory meta-analysis. *Sleep Med Rev* 2018;39:82–97.
17. Miettinen T, Mäntyselkä P, Hagelberg N, Mustola S, Kalso E, Lötsch J. Machine learning suggests sleep as a core factor in chronic pain. *Pain* 2021;162:109–23.
18. Prados G, Miró E, Martínez MP, Sánchez AI, López S, Sáez G. Fibromyalgia: gender differences and sleep-disordered breathing. *Clin Exp Rheumatol* 2013;31:S102–10.
19. Shah MA, Feinberg S, Krishnan E. Sleep-disordered breathing among women with fibromyalgia syndrome. *JCR J Clin Rheumatol* 2006;12:277–81.
20. Lacasse Y, Godbout C, Sériès F. Health-related quality of life in obstructive sleep apnoea. *Eur Respir J* 2002;19:499–503.
21. Arnold WC, Guilleminault C. Upper airway resistance syndrome 2018: non-hypoxic sleep-disordered breathing. *Expet Rev Respir Med* 2019;13:317–26.
22. Onen S-H, Onen F, Albrand G, Decullier E, Chapuis F, Dubray C. Pain tolerance and obstructive sleep apnea in the elderly. *J Am Med Dir Assoc* 2010;11:612–6.
23. Cheattle MD, Foster S, Pinkett A, Lesneski M, Qu D, Dhingra L. Assessing and managing sleep disturbance in patients with chronic pain. *Anesthesiol Clin* 2016;34:379–93.
24. Menefee LA, Cohen MJM, Anderson WR, Doghramji K, Frank ED, Lee H. Sleep disturbance and nonmalignant chronic pain: a comprehensive review of the literature. *Pain Med* 2000;1:156–72.
25. Kushida CA, Littner MR, Morgenthaler T, Alessi CA, Bailey D, Coleman J, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. *Sleep* 2005;28:499–523.
26. Collop NA, Anderson WM, Boehlecke B, Claman D, Goldberg R, Gottlieb DJ, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. *J Clin Sleep Med* 2007;3:737–47.
27. Flemons WW, Douglas NJ, Kuna ST, Rodenstein DO, Wheatley J. Access to diagnosis and treatment of patients with suspected sleep apnea. *Am J Respir Crit Care Med* 2004;169:668–72.
28. Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. Validation of the Berlin questionnaire and American society of anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. *Anesthesiology* 2008;108:822–30.
29. Nagappa M, Liao P, Wong J, Auckley D, Ramachandran SK, Memtsoudis S, et al. Validation of the stop-bang questionnaire as a screening tool for obstructive sleep apnea among different populations: a systematic review and meta-analysis. *PLoS One* 2015;10. <https://doi.org/10.1371/journal.pone.0143697>.
30. Von Korff M, Scher AI, Helmick C, Carter-Pokras O, Dodick DW, Goulet J, et al. United States national pain strategy for population research: concepts, definitions, and pilot data. *J Pain* 2016;17:1068–80.
31. Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP questionnaire. *Anesthesiology* 2008;108:812–21.

32. Vaegter HB, Graven-Nielsen T. Pain modulatory phenotypes differentiate subgroups with different clinical and experimental pain sensitivity. *Pain* 2016;157:1480–8.
33. Vaegter HB, Handberg G, Kent P. (345) Brief psychological screening questions can be useful for ruling out psychological conditions in patients with chronic pain. *J Pain* 2017;18:S61.
34. Plesner KB, Vaegter HB. Symptoms of fibromyalgia according to the 2016 revised fibromyalgia criteria in chronic pain patients referred to multidisciplinary pain rehabilitation: influence on clinical and experimental pain sensitivity. *J Pain* 2018;19:777–86.
35. Goyal M, Johnson J. Obstructive sleep apnea diagnosis and management. *Mo Med* 1997;114:120–4.
36. Cairns A, Wickwire E, Schaefer E, Nyanjom D. A pilot validation study for the NOX T3TM portable monitor for the detection of OSA. *Sleep Breath* 2014;18:609–14.
37. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, et al. Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. *J Clin Sleep Med* 2012;8:597–619.
38. Epstein LJ, Kristo D, Strollo PJ, Friedman N, Malhotra A, Patil SP, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. *J Clin Sleep Med* 2009;5:263–76.
39. Liistro G, Rombaux P, Belge C, Dury M, Aubert G, Rodenstein DO. High Mallampati score and nasal obstruction are associated risk factors for obstructive sleep apnoea. *Eur Respir J* 2003;21:248–52.
40. Vaegter HB, Christoffersen LO, Enggaard TP, Holdgaard DEM, Lefevre TN, Eltved R, et al. Socio-demographics, pain characteristics, quality of life and treatment values before and after specialized interdisciplinary pain treatment: results from the Danish clinical pain registry (PainData). *J Pain Res* 2021;14:1215–30.
41. Haefeli M, Elfering A. Pain assessment. *Eur Spine J* 2006;15:17–24.
42. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. *Ann Acad Med Singapore* 1994;23:129–38.
43. The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. *Health Pol* 1990;16:199–208.
44. Nordin M, Åkerstedt T, Nordin S. Psychometric evaluation and normative data for the karolinska sleep questionnaire. *Sleep Biol Rhythms* 2013;11:216–26.
45. Kecklund G. The psychometric properties of the Karolinska Sleep Questionnaire. *J Sleep Res* 1992;1(1 Suppl):113.
46. Clark AJ, Dich N, Lange T, Jennum P, Hansen ÅM, Lund R, et al. Impaired sleep and allostatic load: cross-sectional results from the Danish Copenhagen Aging and Midlife Biobank. *Sleep Med* 2014;15:1571–8.
47. Morin CM. *Insomnia: psychological assessment and management*. New York, NY, US: Guilford Press; 1993.
48. Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. *Sleep Med* 2001;2:297–307.
49. Gagnon C, Bélanger L, Ivers H, Morin CM. Validation of the insomnia severity index in primary care. *J Am Board Fam Med* 2013;26:701–10.
50. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. *Sleep* 1991;14:540–5.
51. Landis JR, Koch GG. The measurement of observer agreement for categorical data. *Biometrics* 1977;33:159.
52. Chung F, Wong J, Bellingham G, Lebovic G, Singh M, Waseem R, et al. Predictive factors for sleep apnoea in patients on opioids for chronic pain. *BMJ Open Respir Res* 2019;6:1–10.
53. Abeler K, Friberg O, Engström M, Sand T, Bergvik S. Sleep characteristics in adults with and without chronic musculoskeletal pain: the role of mental distress and pain catastrophizing. *Clin J Pain* 2020;36:707–15.
54. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, et al. Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. *Lancet Respir Med* 2015;3:310–8.
55. Finn L, Young T, Palta M, Fryback DG. Sleep-disordered breathing and self-reported general health status in the Wisconsin Sleep Cohort Study. *Sleep* 1998;21:701–6.
56. BaHammam AS, Obeidat A, Barataman K, Bahammam SA, Olaish AH, Sharif MM. A comparison between the AASM 2012 and 2007 definitions for detecting hypopnea. *Sleep Breath* 2014;18:767–73.
57. Pampati S, Manchikanti L. What is the prevalence of symptomatic obstructive sleep apnea syndrome in chronic spinal pain patients? An assessment of the correlation of OSAS with chronic opioid therapy, obesity, and smoking. *Pain Physician* 2016;19:E569–79.
58. Allen KD, Renner JB, DeVellis B, Helmick CG, Jordan JM. Osteoarthritis and sleep: the Johnston County osteoarthritis project. *J Rheumatol* 2008;35:1102–7.
59. Taylor SS, Hughes JM, Coffman CJ, Jeffreys AS, Ulmer CS, Oddone EZ, et al. Prevalence of and characteristics associated with insomnia and obstructive sleep apnea among veterans with knee and hip osteoarthritis. *BMC Musculoskel Disord* 2018;19:1–8.
60. Mokhlesi B, Ham SA, Gozal D. The effect of sex and age on the comorbidity burden of OSA: an observational analysis from a large nationwide US health claims database. *Eur Respir J* 2016;47:1162–9.
61. Fietze I, Laharnar N, Obst A, Ewert R, Felix SB, Garcia C, et al. Prevalence and association analysis of obstructive sleep apnea with gender and age differences – results of SHIP-trend. *J Sleep Res* 2019;28:1–9.
62. Rose AR, Catcheside PG, McEvoy RD, Paul D, Kapur D, Peak E, et al. Sleep disordered breathing and chronic respiratory failure in patients with chronic pain on long term opioid therapy. *J Clin Sleep Med* 2014;10:847–52.
63. Webster LR, Choi Y, Desai H, Webster L, Grant BJB. Sleep-disordered breathing and chronic opioid therapy. *Pain Med* 2008;9:425–32.
64. Walker JM, Farney RJ, Rhondeau SM, Boyle KM, Valentine K, Cloward TV, et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. *J Clin Sleep Med* 2007;3:455–61.
65. Mubashir T, Nagappa M, Esfahanian N, Botros J, Arif AA, Suen C, et al. Prevalence of sleep-disordered breathing in opioid users with chronic pain: a systematic review and meta-analysis. *J Clin Sleep Med* 2020;16:961–9.
66. Charokopos A, Card ME, Gunderson C, Steffens C, Bastian LA. The association of obstructive sleep apnea and pain outcomes in adults: a systematic review. *Pain Med* 2018;19:S69–75.
67. Luyster FS, Buysse DJ, Strollo PJ. Comorbid insomnia and obstructive sleep apnea: challenges for clinical practice and research. *J Clin Sleep Med* 2010;6:196–204.
68. Campbell CM, Buenaver LF, Finan P, Bounds SC, Redding M, McCauley L, et al. Sleep, pain catastrophizing, and central

- sensitization in knee osteoarthritis patients with and without insomnia. *Arthritis Care Res* 2015;67:1387–96.
69. Vaegter HB, Støten M, Silseth SL, Erlangsen A, Handberg G, Sondergaard S, et al. Cause-specific mortality of patients with severe chronic pain referred to a multidisciplinary pain clinic: a cohort register-linkage study. *Scand J Pain* 2019;19:93–9.
 70. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. *J Am Coll Cardiol* 2017;69:841–58.
 71. Punjabi NM, Caffo BS, Goodwin JL, Gottlieb DJ, Newman AB, O'Connor GT, et al. Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med* 2009;6. <https://doi.org/10.1371/journal.pmed.1000132>.
 72. Drager LF, McEvoy RD, Barbe F, Lorenzi-Filho G, Redline S. Sleep apnea and cardiovascular disease: lessons from recent trials and need for team science. *Circulation* 2017;136:1840–50.
 73. Lipford MC, Wahnner-Roedler DL, Welsh GA, Mandrekar J, Thapa P, Olson EJ. Correlation of the Epworth sleepiness scale and sleep-disordered breathing in men and women. *J Clin Sleep Med* 2019;15:33–8.
 74. Kadhim K, Middeldorp ME, Elliott AD, Jones D, Hendriks JML, Gallagher C, et al. Self-reported daytime sleepiness and sleep-disordered breathing in patients with atrial fibrillation: SNOozE-AF. *Can J Cardiol* 2019;35:1457–64.
 75. Cho YW, Kim KT, Moon HJ, Korostyshevskiy VR, Motamedi GK, Yang KI. Comorbid insomnia with obstructive sleep apnea: clinical characteristics and risk factors. *J Clin Sleep Med* 2018;14:409–17.
 76. Zhang Y, Ren R, Lei F, Zhou J, Zhang J, Wing YK, et al. Worldwide and regional prevalence rates of co-occurrence of insomnia and insomnia symptoms with obstructive sleep apnea: a systematic review and meta-analysis. *Sleep Med Rev* 2019;45:1–17.
 77. Mundt JM, Eisenschenk S, Robinson ME. An examination of pain's relationship to sleep fragmentation and disordered breathing across common sleep disorders. *Pain Med* 2018;19:1516–24.
 78. Ng SS, Tam W, Chan TO, To KW, Ngai J, Chan KKP, et al. Use of Berlin questionnaire in comparison to polysomnography and home sleep study in patients with obstructive sleep apnea. *Respir Res* 2019;20:1–8.
 79. Senaratna CV, Perret JL, Matheson MC, Lodge CJ, Lowe AJ, Cassim R, et al. Validity of the Berlin questionnaire in detecting obstructive sleep apnea: a systematic review and meta-analysis. *Sleep Med Rev* 2017;36:116–24.
 80. Tentindo GS, Fishman S, Li C-S, Wang Q, Brass SD. The prevalence and awareness of sleep apnea in patients suffering chronic pain: an assessment using the STOP-Bang sleep apnea questionnaire. *Nat Sci Sleep* 2018;10:217–24.
 81. McDaid C, Griffin S, Weatherly H, Durée K, van der Burgt M, van Hout S, et al. Continuous positive airway pressure devices for the treatment of obstructive sleep apnoea-hypopnoea syndrome: a systematic review and economic analysis. *Health Technol Assess* 2009;13. <https://doi.org/10.3310/hta13040>.
 82. Bianchi MT, Goparaju B. Potential underestimation of sleep apnea severity by at-home kits: rescoring in-laboratory polysomnography without sleep staging. *J Clin Sleep Med* 2017;13:551–5.